Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

Breast Cancer Research and Treatment

Volumn 147, Issue 3, 2014, Pages 609-616

  Chen, Lu ^a,b   Linden, Hannah M ^a,c   Anderson, Benjamin O ^a,c   Li, Christopher I ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Progesterone receptor; Survival; Time trend

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION RESEARCH; RACE; SURVIVAL RATE; SURVIVAL TIME; TREND STUDY; UNITED STATES; BREAST TUMOR; EPIDEMIOLOGY; METABOLISM; MORTALITY; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEER PROGRAM; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84918513849     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3112-6     Document Type: Article

References (44)

1. Howlader N, Noone AM, Krapcho M, et al (2013) SEER cancer statistics review, 1975–2010. http://seer.cancer.gov/csr/1975_2010/. Accessed 14 August 2014
2. Howlader N, Noone AM, Krapcho M, et al (2014) SEER cancer statistics review, 1975–2011. http://seer.cancer.gov/csr/1975_2010/. Accessed 14 August 2014
3. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792
4. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52
5. Holleczek B, Brenner H (2012) Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12:317
6. Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683–1690
7. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6
8. Ademuyiwa FO, Groman A, Hong C-C et al (2013) Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat 138:241–248
9. Bartlett JMS, Brookes CL, Robson T et al (2011) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531–1538
10. Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065
11. Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:1998–2005
12. Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(Suppl 7):vii10–vii14
13. Smith RE, Good BC (2003) Chemoprevention of breast cancer and the trials of the national surgical adjuvant breast and bowel project and others. Endocr Relat Cancer 10:347–357
14. National cancer institute adjusted AJCC 6th ed. T, N, M, and stage—SEER documentation. http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/. Accessed 23 Jun 2014
15. Statistical research and applications branch NCI jointpoint regression program, Version 4.0.1
16. Kim HJ, Fay MP, Feuer EJMD (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351
17. Bérubé S, Provencher L, Robert J et al (2007) Quantitative exploration of possible reasons for the recent improvement in breast cancer survival. Breast Cancer Res Treat 106:419–431
18. Dawood S, Broglio K, Gonzalez-Angulo AM et al (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891–4898
19. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15 year survival:an overview of the randomized trials. Lancet 365:1687–1717
20. Colozza M, de Azambuja E, Personeni N et al (2007) Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12:253–270
21. Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 1:E1–E25
22. Mitri Z, Constantine T, O’Regan R (2012) The HER2 Receptor in Breast Cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193
23. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502
24. Hammond MEH, Hayes DF, Wolff AC et al (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195–197
25. Cano G, Milanezi F, Leitão D et al (2003) Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 29:207–211
26. Cheang MCU, Treaba DO, Speers CH et al (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637–5644
27. Welsh AW, Harigopal M, Wimberly H et al (2013) Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol 21:139–147
28. Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261
29. Yu K-D, Liu G-Y, Di G-H et al (2007) Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast 16:307–315
30. Carlson RW, Hudis CA, Pritchard KI (2006) Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Cancer Netw 4:971–979
31. Hunt BR, Whitman S, Hurlbert MS (2014) Increasing Black:white disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 38:118–123
32. Menashe I, Anderson WF, Jatoi I, Rosenberg PS (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101:993–1000
33. Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321
34. Gerend MA, Pai M (2008) Social determinants of Black–White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev 17:2913–2923
35. Silber JH, Rosenbaum PR, Clark AS et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389–397
36. Lepeak L, Tevaarwerk A, Jones N et al (2011) Persistence in breast cancer disparities between African Americans and whites in Wisconsin. WMJ 110:21–25
37. Jatoi I, Anderson WF, Rao SR, Devesa SS (2005) Breast cancer trends among black and white women in the United States. J Clin Oncol 23:7836–7841
38. DeLancey JOL, Thun MJ, Jemal A, Ward EM (2008) Recent trends in Black–White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev 17:2908–2912
39. Livaudais JC, Lacroix A, Chlebowski RT et al (2013) Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women’s health initiative. Cancer Epidemiol Biomarkers Prev 22:365–373
40. Fedewa SA, Ward EM, Stewart AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28:4135–4141
41. Sail K, Franzini L, Lairson D, Du X (2012) Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer. Ethn Health 17:309–323
42. Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839–846
43. Lehtimäki T, Lundin M, Linder N et al (2011) Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res 13:R134
44. Population Characteristics—SEER registries. http://seer.cancer.gov/registries/characteristics.html. Accessed 31 Jan 2013